Physician profile
Tabitha Melvin
NPI 1376513564
$2,705.84
in general payments reported to CMS, 2019-2025
14 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,066 · 2022: $237 · 2023: $576 · 2024: $468 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.45 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $703.45 | 2021-2025 | |
| Janssen Biotech, INC. | $540.59 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $386.07 | 2021-2025 | Winlevi, Absorica Ld |
| Abbvie INC. | $275.96 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $174.33 | 2023 | |
| Ucb, INC. | $146.12 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $132.45 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $125.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Biofrontera INC. | $30.31 | 2021-2025 | Ameluz |
| Galderma Laboratories, L.P. | $28.87 | 2021 | |
| Dermira, INC. | $16.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Melvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.